SCHEMBL1770195

SCHEMBL1770195

Cn1cnnc1SCC(=O)C1(c2ccc(Cl)cc2)CC1

nearest known ligand 0.54

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
HSD11B1 P28845 1/20 0.54
TP53 P04637 1/20 0.51
SMN1; SMN2 Q16637 1/20 0.51
LMNA P02545 2/20 0.48
KMT2A Q03164 3/20 0.48
ALDH1A1 P00352 6/20 0.47
MAPT P10636 2/20 0.47
L3MBTL1 Q9Y468 1/20 0.46
CYP1A2 P05177 1/20 0.46
CYP3A4 P08684 1/20 0.46
CYP2C9 P11712 1/20 0.46
CYP2C19 P33261 1/20 0.46
HSD17B10 Q99714 1/20 0.46
KDM4E B2RXH2 1/20 0.46
GAA P10253 1/20 0.46
RAB9A P51151 1/20 0.46
TDP1 Q9NUW8 1/20 0.46
MEN1 O00255 1/20 0.45
ATM Q13315 1/20 0.45
POLB P06746 1/20 0.45

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL1770305 0.95 HSD11B1 (0.55) HSD11B1TP53SMN1; SMN2LMNAKMT2A
SCHEMBL1769927 0.81 ALDH1A1 (0.61) TP53SMN1; SMN2LMNAKMT2AALDH1A1
SCHEMBL1770056 0.77 ALDH1A1 (0.59) TP53SMN1; SMN2LMNAKMT2AALDH1A1
SCHEMBL1770153 0.77 ALDH1A1 (0.59) TP53SMN1; SMN2LMNAKMT2AALDH1A1
SCHEMBL1770094 0.76 ALDH1A1 (0.58) HSD11B1TP53SMN1; SMN2KMT2AALDH1A1
SCHEMBL1770036 0.73 TP53 (0.53) HSD11B1TP53SMN1; SMN2LMNAKMT2A
SCHEMBL1770425 0.73 HSD11B1 (0.40) HSD11B1ALDH1A1
SCHEMBL1770088 0.70 HSD11B1 (1.00) HSD11B1TP53LMNAKMT2AALDH1A1
SCHEMBL2491894 0.70 L3MBTL1 (0.62) HSD11B1LMNAKMT2AALDH1A1MAPT
SCHEMBL13688850 0.70 HSD11B1 (0.44) HSD11B1ALDH1A1MAPT

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20110112151-A1 COMPOUND CAPABLE OF INHIBITING 11-BETA HYDROXYSTERIOD DEHYDROGENASE STERIX LIMITED (GB) 2011-05-12 US disclosed
US-20110112151-A1 COMPOUND CAPABLE OF INHIBITING 11-BETA HYDROXYSTERIOD DEHYDROGENASE STERIX LIMITED (GB) 2011-05-12 US disclosed
US-20110112151-A1 COMPOUND CAPABLE OF INHIBITING 11-BETA HYDROXYSTERIOD DEHYDROGENASE STERIX LIMITED (GB) 2011-05-12 US disclosed
WO-2009106817-A2 COMPOUND STERIX LIMITED (GB) 2009-09-03 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20110112151-A1 COMPOUND CAPABLE OF INHIBITING 11-BETA HYDROXYSTERIOD DEHYDROGENASE HSD11B1, HSD11B2, HSD3B1 HSD11B1 1/4885TP53 4033/4885SMN1; SMN2 2765/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.